Search

Displaying results 2611 - 2620 of 10000 in total
  1. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.

  2. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    [A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast … This malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality.

  3. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    FDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the

  4. Drug

    gamma-Aminobutyric acid

    go.drugbank.com/drugs/DB02530
    ApprovedInvestigational

    The most common inhibitory neurotransmitter in the central nervous system.

    Synonyms: γ-amino-n-butyric acidMixtures: Theraproxen-500, Theraprofen-800
  5. Drug

    Istiratumab

    go.drugbank.com/drugs/DB15363
    Investigational

    Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).

  6. Drug

    Tyrothricin

    go.drugbank.com/drugs/DB13503
    ApprovedWithdrawn

    Nevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity [L4019, L4021, L4022], although certain formulations that are safe for human use like throat lozenges do … Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus

    Mixtures: Dorithricin Halstabletten Classic 0,5 mg / 1,0 mg / 1,5 mg Lutschtabletten, Dorithricin Halstabletten Waldbeergeschmack 0,5 mg / 1,0 mg / 1,5 mg Lutschtabletten
  7. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S. … The defribrinogenation of blood results in an anticoagulant effect.

  8. Drug

    Sulfadoxine

    go.drugbank.com/drugs/DB01299
    ApprovedInvestigationalWithdrawn

    A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.

    Mixtures: SULFADOXINA 500 MG + PIRIMETAMINA 25 MG TABLETAS
  9. Drug

    AMG-208

    go.drugbank.com/drugs/DB08079
    Investigational

    AMG-208 has been used in trials studying the treatment of Cancer, Tumors, Oncology, Prostate Cancer, and Oncology Patients, among others.

  10. Drug

    Flibanserin

    go.drugbank.com/drugs/DB04908
    ApprovedInvestigational

    in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. … Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015.